---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000063"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:18:48.150605+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arvinas/Pfizer report updated Phase 1b combo data of vepdegestrant + palbociclib; consistent with prior

## Summary
- Clinical benefit rate 63% across all doses; at RP3D 200 mg, CBR 67%; ORR 42% overall, 53% at 200 mg.
- Median progression-free survival 11.2 months across doses; at 200 mg, mPFS 13.9 months (95% CI: 8.1-NR).
- Median duration of response 14.6 months in 13 responders; safety consistent with prior, Grade 3/4 neutropenia 91%.
- ctDNA showed marked reduction in tumor fraction (-98.9%) after one cycle regardless of ESR1 mutation status.

## SEC filing metadata
- accession: 0001655759-24-000063
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000063/0001655759-24-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000063/arvn-20240516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000063
- JSON: https://secwatch.observer/filing/0001655759-24-000063.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.